Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects

Cell Calcium

Volumn 54, Issue 2, 2013, Pages 57-70

  Zhang, X H ^a   Haviland, S ^a   Wei, H ^a   Saric T ^b   Fatima, A ^b   Hescheler, J ^b   Cleemann, L ^a   Morad, M ^a  

^a CLEMSON UNIVERSITY   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Calcium signaling; CICR gain; CPVT; Mutation in RyR2 gene; Pluripotent stem cells

Indexed keywords

CAFFEINE; CALCIUM; ISOPRENALINE; RYANODINE RECEPTOR 2; SODIUM CALCIUM EXCHANGE PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; RYANODINE RECEPTOR;

ARTICLE; CALCIUM CURRENT; CALCIUM SIGNALING; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL FUNCTION; CELL MUTANT; CELL STIMULATION; CONTROLLED STUDY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PATCH CLAMP; PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; RYR2 GENE; ADULT; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CICR GAIN; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; HEART VENTRICLE TACHYCARDIA; IN VITRO STUDY; METABOLISM; MUTATION IN RYR2 GENE; PATCH CLAMP TECHNIQUE; PATHOLOGY; PHYSIOLOGY; DRUG EFFECTS;

IPS;

CALCIUM SIGNALING; CICR GAIN; CPVT; MUTATION IN RYR2 GENE; PLURIPOTENT STEM CELLS;

ADRENERGIC AGONISTS; ADULT; CAFFEINE; CALCIUM; CALCIUM SIGNALING; CATECHOLAMINES; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; HUMANS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PLURIPOTENT STEM CELLS; POINT MUTATION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR; IN VITRO TECHNIQUES;

EID: 84880513096     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2013.04.004     Document Type: Article

References (48)

1. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
2. Gupta M.K., Illich D.J., Gaarz A., Matzkies M., Nguemo F., Pfannkuche K., Liang H., Classen S., Reppel M., Schultze J.L., Hescheler J., Saric T. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Developmental Biology 2010, 10:98.
3. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research 2009, 104:e30-e41.
4. Hoekstra M., Mummery C.L., Wilde A.A., Bezzina C.R., Verkerk A.O. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Frontiers in Physiology 2012, 3:346.
5. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., Dorn T., Goedel A., Hohnke C., Hofmann F., Seyfarth M., Sinnecker D., Schomig A., Laugwitz K.L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. New England Journal of Medicine 2010, 363:1397-1409.
6. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., Boulos M., Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
7. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal 2011, 32:952-962.
8. Malan D., Friedrichs S., Fleischmann B.K., Sasse P. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circulation Research 2011, 109:841-847.
9. Fatima A., Xu G., Shao K., Papadopoulos S., Lehmann M., Arnaiz-Cot J.J., Rosa A.O., Nguemo F., Matzkies M., Dittmann S., Stone S.L., Linke M., Zechner U., Beyer V., Hennies H.C., Rosenkranz S., Klauke B., Parwani A.S., Haverkamp W., Pfitzer G., Farr M., Cleemann L., Morad M., Milting H., Hescheler J., Saric T. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cellular Physiology and Biochemistry 2011, 28:579-592.
10. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., Hyttinen J., Kontula K., Swan H., Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setala K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Disease Models and Mechanisms 2012, 5:220-230.
11. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., Salvatori D., Oostwaard D.W., Wilde A.A., Bezzina C.R., Verkerk A.O., Freund C., Mummery C.L. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125:3079-3091.
12. Wier W.G. Gain and cardiac E-C coupling: revisited and revised. Circulation Research 2007, 101:533-535.
13. 2+ channels and ryanodine receptors in rat ventricular myocytes. Journal of General Physiology 1996, 108:435-454.
14. Bers D.M., Guo T. Calcium signaling in cardiac ventricular myocytes. Annals of the New York Academy of Sciences 2005, 1047:86-98.
15. 2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells 2006, 24:236-245.
16. Liu J., Fu J.D., Siu C.W., Li R.A. Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. Stem Cells 2007, 25:3038-3044.
17. Sedan O., Dolnikov K., Zeevi-Levin N., Leibovich N., Amit M., Itskovitz-Eldor J., Binah O. 1,4,5-Inositol trisphosphate-operated intracellular Ca(2+) stores and angiotensin-II/endothelin-1 signaling pathway are functional in human embryonic stem cell-derived cardiomyocytes. Stem Cells 2008, 26:3130-3138.
18. Itzhaki I., Rapoport S., Huber I., Mizrahi I., Zwi-Dantsis L., Arbel G., Schiller J., Gepstein L. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PLoS ONE 2011, 6:e18037.
19. Zhu W.Z., Santana L.F., Laflamme M.A. Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes. PLoS ONE 2009, 4:e5407.
20. 2+ current trigger. Journal of Physiology 2004, 556:463-480.
21. 2+ exchanger expressed in human cell lines. Journal of Physiology 2003, 548:677-689.
22. Marks A.R., Priori S., Memmi M., Kontula K., Laitinen P.J. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. Journal of Cellular Physiology 2002, 190:1-6.
23. Lehnart S.E., Wehrens X.H., Marks A.R. Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biochemical and Biophysical Research Communications 2004, 322:1267-1279.
24. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circulation Research 2005, 97:1173-1181.
25. 2+ handling and arrhythmogenesis. Circulation Research 2011, 108:871-883.
26. Goddard C.A., Ghais N.S., Zhang Y., Williams A.J., Colledge W.H., Grace A.A., Huang C.L. Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts. Acta Physiologica (Oxford) 2008, 194:123-140.
27. 2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circulation Research 2009, 104:201-209. 12p following 209.
28. Suetomi T., Yano M., Uchinoumi H., Fukuda M., Hino A., Ono M., Xu X., Tateishi H., Okuda S., Doi M., Kobayashi S., Ikeda Y., Yamamoto T., Ikemoto N., Matsuzaki M. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca(2)(+)release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation 2011, 124:682-694.
29. Cerrone M., Colombi B., Santoro M., di Barletta M.R., Scelsi M., Villani L., Napolitano C., Priori S.G. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circulation Research 2005, 96:e77-e82.
30. 2+-buffered rat atrial myocytes. Journal of Physiology 2005, 567:905-921.
31. 2+ release sites in rat cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:10984-10989.
32. Tufan H., Zhang X.H., Haghshenas N., Sussman M.A., Cleemann L., Morad M. Cardiac progenitor cells engineered with Pim-1 (CPCeP) develop cardiac phenotypic electrophysiological properties as they are co-cultured with neonatal myocytes. Journal of Molecular and Cellular Cardiology 2012, 53:695-706.
33. Morad M., Goldman Y. Excitation-contraction coupling of heart muscle: membrane control of development of tension. Progress in Biophysics and Molecular Biology 1973, 27:257-313.
34. 2+ transients and contraction. Journal of Physiology 1991, 432:283-312.
35. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Annual Review of Physiology 2008, 70:23-49.
36. 2+ release in rat atrial myocytes. Circulation Research 2003, 92:e1-e11.
37. 2+ transients in rat cardiac myocytes: possible mechanisms and role of mitochondria. Journal of Physiology 2008, 586:1379-1397.
38. Bassani J.W., Yuan W., Bers D.M. Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. American Journal of Physiology 1995, 268:C1313-C1319.
39. Solovyova N., Veselovsky N., Toescu E.C., Verkhratsky A. Ca(2+) dynamics in the lumen of the endoplasmic reticulum in sensory neurons: direct visualization of Ca(2+)-induced Ca(2+) release triggered by physiological Ca(2+) entry. EMBO Journal 2002, 21:622-630.
40. Kujala K., Paavola J., Lahti A., Larsson K., Pekkanen-Mattila M., Viitasalo M., Lahtinen A.M., Toivonen L., Kontula K., Swan H., Laine M., Silvennoinen O., Aalto-Setala K. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS ONE 2012, 7:e44660.
41. 2+ cross signaling between DHP and ryanodine receptors in rat ventricular myocytes. American Journal of Physiology 1999, 276:H1178-H1189.
42. 2+ current amplitude and open channel probability. Circulation Research 2007, 101:590-597.
43. 2+ signalling in rat atrial myocytes: possible role of the alpha1C carboxyl terminal. Journal of Physiology 2003, 552:437-447.
44. 2+ dependence of inactivation. Biological Chemistry 1997, 272:3560-3566.
45. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. Journal of Clinical Investigation 2008, 118:2230-2245.
46. Liu N., Colombi B., Memmi M., Zissimopoulos S., Rizzi N., Negri S., Imbriani M., Napolitano C., Lai F.A., Priori S.G. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circulation Research 2006, 99:292-298.
47. Itzhaki I., Maizels L., Huber I., Gepstein A., Arbel G., Caspi O., Miller L., Belhassen B., Nof E., Glikson M., Gepstein L. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. Journal of the American College of Cardiology 2012, 60:990-1000.
48. Jung C.B., Moretti A., Mederos y Schnitzler M., Iop L., Storch U., Bellin M., Dorn T., Ruppenthal S., Pfeiffer S., Goedel A., Dirschinger R.J., Seyfarth M., Lam J.T., Sinnecker D., Gudermann T., Lipp P., Laugwitz K.L. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Molecular Medicine 2012, 4:180-191.